Aptamer and RVG functionalized gold nanorods for targeted photothermal therapy of neurotropic virus infection in the mouse brain

The infection of the neurotropic virus damages the central nervous system (CNS) and often leads to humans' fatal symptoms. Rabies is a lethal disease caused by a typical neurotropic virus, rabies virus (RABV). To date, there is no effective clinical therapy for rabies. In this report, an aptamer conjugated RVG-Apt-PEG-Silica gold nanorods (AuNR)-based photothermal therapy (PTT) was developed and evaluated in a mouse model. The DNA aptamer was conjugated on the nanoparticle to provide specificity for targeting RABV glycoprotein in cells and mouse brains. A 29-aa rabies virus glycopeptide (RVG) was conjugated on the nanoparticle to enhance CNS delivery. The virions were inactivated in cell supernatant, and an approximately 100-fold decrease of viral load was observed in cells 5 min post-PTT. This AuNR did not cause distinct apoptosis, inflammation, or pathological lesion in the mouse brains post PTT. At 3 day post-infection, significantly enhanced survival ratio (60%) was observed in mice received PTT compared with the mice without PTT. In the PTT group, both the viral RNA level and the distribution of RABV in mouse brains were significantly decreased. Collectively, aptamer conjugated RVG-Apt-PEG-Silica AuNR-based PTT could be considered as a promising strategy for clinical treatment with neurotropic virus infection.

Automated summary

Rabies, a lethal disease caused by a neurotropic virus, currently lacks effective clinical therapy. A photothermal therapy using aptamer conjugated RVG-Apt-PEG-Silica gold nanorods showed promising results in reducing viral load and increasing survival rate in a mouse model.